Table 2. The baseline and clinical characteristics of patients according to α-blocker regimen.
| Tamsulosin 0.2 mg | Alfuzosin 10 mg | Doxazosin GITS 4 mg | Terazosin 2 mg | |
|---|---|---|---|---|
| No | 385 | 203 | 197 | 168 |
| Age | 62.5±7.0 | 61.8±8.2 | 66.1±6.0 | 64.3±7.6 |
| IPSS (total) | ||||
| Baseline | 16.0±2.1* | 15.5±2.6* | 16.5±1.9* | 15.8±2.4* |
| Follow up | 11.6±2.0* | 10.6±1.8* | 12.0±1.3* | 10.6±1.5* |
| QOL | ||||
| Baseline | 3.7±0.2* | 3.9±0.5* | 4.0±0.4* | 3.9±0.5 |
| Follow up | 3.0±0.3* | 3.1±0.7* | 3.3±0.6* | 3.4±0.3 |
| Prostate volume (cc) | 35.8±6.1 | 32.2±4.5 | 41.3±7.1 | 38.3±5.8 |
| PSA (ng ml−1) | 2.5±0.2 | 1.9±0.3 | 2.4±0.5 | 1.7±0.6 |
| Qmax (ml s−1) | 11.0±1.7 | 11.7±0.5 | 10.6±0.8 | 10.0±1.3 |
| Residual urine volume (cc) | 60.6±10.2 | 51.6±7.1 | 67.9±8.4 | 62.4±6.6 |
| Baseline BP (mm Hg) | ||||
| Systolic | 129.4±6.8 | 130.1±9.3 | 131.3±8.3* | 129.8±7.9 |
| Diastolic | 83.6±9.2 | 84.5±5.9 | 84.9±6.7 | 85.8±6.2 |
| BP following ‘add on' treatment | ||||
| Systolic | 127.6±7.2 | 126.8±10.6 | 125.1±10.9* | 126.2±9.1 |
| Diastolic | 83.3±9.4 | 84.2±8.0 | 83.5±6.9 | 84.1±7.8 |
| Adverse events following ‘add on' treatment | ||||
| Dizziness, N(%) | 11 (2.2) | 7 (3.4) | 10 (5.1) | 8 (4.8) |
| Postural hypotension, N(%) | 7 (1.9) | 5 (2.5) | 11 (5.6) | 7 (4.2) |
| Etc., N(%) | 3 (0.8) | 2 (1.0) | 2 (1.0) | 5 (3.0) |
Abbreviations: BP, blood pressure; GITS, gastrointestinal therapeutic system; IPSS, international prostate symptom score; Qmax, urinary flow rate; QOL, quality of life.
The values for age, blood pressure, prostate volume, PSA, IPSS, QOL, Qmax, and residual urine volume are means ±s.d.
*P<0.05 by ANCOVA test.